Yervoy | Essential Guide to Prescription Drugs

WILL Interview

Overcoming Osteoporosis
An Interview with Dr. Jim Rybacki

Recent blog posts

Europe Medicines Committee takes a different view than US FDA committee and give go ahead for Xarelto in acute coronary syndrome
Can a side effect help you?
Essential Guide to Prescription Drugs now available- PR Newswire
Viagra for heart failure?--RELAX and The American College of Cardiology meeting in San Francisco
Did you or a family member have a stroke or a heart attack? Could they be an undiagnosed diabetic too?
Osphena (ospemifene) a new medicine for painful/difficult intercourse in women now FDA approved
A CHANCE result for an older drug preventing strokes or will a US study make the POINT?
Drug newly approved for children in lymphoblastic leukemia
Love that woman? Give her blueberries and strawberries 3 times a week
Tuesday morning at the American Heart in LA--Niacin/Niaspan and a closer look at AIM HIGH

Follow RybackiKnows on Twitter

For Email Marketing you can trust

Heart Graphic

Products we trust

Smart For Your Heart
(Click Below)

Shopping cart

There are no products in your shopping cart.

0 Items

Total: $0.00

Yervoy

The Essential Guide to Prescription Drugs, 12 Top Meds for 2012 now available in full color printed and on Kindle

The Essential Guide to Prescription Drugs, 12 Top Meds for 2012 is now available from Amazon in a full-color printed version.

Dr Jim Rybacki's blog | Tags: Abnormal Cholesterol, Alzheimers, Arthritis, Chronic Pain, Depression, Diabetes, Heart Attacks, High Blood Pressure, Oncology (Cancer), Osteoporosis, Poor Leg Circulation (PAD), Side Effects, Stroke, Weight Loss, 12 Top Meds for 2012, apidra, aspirin, atorvastatin, Botox, Clopidogrel, Crestor, Diovan, escitalopram, esomeprazole, Essential Guide, Humalog, Insulin, ipilimumab, Lantus, Lexapro, Lipitor, Livalo, Nexium, niacin, Niaspan, Plavix, Rivaroxaban, rosuvastatin, simvastatin, the essential guide to prescription drugs, Valsartan, Xarelto, Yervoy, Zocor

Dr. Rybacki to be a guest on Conversations with Peter Solomon WIP, 94.1 FM April 8th 7:30 AM to 8 AM

essential guide to prescription drugs, 12 top meds for 2012 I'll be a guest on Conversations with Peter solomon on WIP AM and FM (94.1 FM) in Philadelphia, Sunday, April 8th from 7:30 AM to 8 AM.

Dr Jim Rybacki's blog | Tags: Abnormal Cholesterol, Alzheimers, Arthritis, Chronic Pain, Depression, Diabetes, Heart Attacks, High Blood Pressure, Oncology (Cancer), Osteoporosis, Poor Leg Circulation (PAD), Side Effects, Stroke, Weight Loss, 12 Top Meds for 2012, aspirin, Clopidogrel, Diovan, escitalopram, esomeprazole, Insulin, ipilimumab, Lexapro, Nexium, Plavix, Rivaroxaban, the essential guide to prescription drugs, Xarelto, Yervoy

Yervoy rejected by NICE, but what about the patients?

drummer How large a charge is too large?

Tags: Oncology (Cancer), benefit versus risk, essential, expense, high cost medications, ipilimumab, Melanoma, NICE, outcomes, pharmacoeconomics, skin cancer, Yervoy

Zelboraf (vemurafenib)--New hope in melanoma or combination therapy option?

beautiful young woman The first of a new kind of lab test and a first-in-the-class therapy have been approved by the FDA. Zelboraf (vemurafenib) was approved by the FDA under the priority review program.

Tags: Abnormal Cholesterol, Alzheimers, Arthritis, Chronic Pain, Depression, Diabetes, Heart Attacks, High Blood Pressure, Oncology (Cancer), Osteoporosis, Poor Leg Circulation (PAD), Side Effects, Stroke, Weight Loss, advanced melanoma, BRAF, BRAF protein, cobas 4800 BRAF V600 Mutation Test, FDA, FDA priority review, ipi, ipilimumab, late-stage, Melanoma, metastatic melanoma, phosensitivity, phototoxicity, progression-free survival, Sun exposure, unresectable, V600E, vemurafenib, Yervoy, Zelboraf

Yervoy (ipilimumab) abstracts and valuable new information

Looking more closely at the ipilimumab (Yervoy) abstracts from the American Society of Clinical Oncology (ASCO) meeting shows that Read more

Tags: Abnormal Cholesterol, Alzheimers, Arthritis, Chronic Pain, Depression, Diabetes, Heart Attacks, High Blood Pressure, Oncology (Cancer), Osteoporosis, Poor Leg Circulation (PAD), Side Effects, Stroke, Weight Loss, Avastin, bevacizumab, BRAF, BRAF 600 E, brain metastasis, colitis, fotemustin, interleukin, interleukin 17, ipilimumab, Melanoma, Muphoran, neoadjuvant, overall survival, safety profile, side effects, Yervoy

Yervoy (ipilimumab) approved for melanoma by the FDA

sears tower A medicine which first received notariety at the American Society of Clinical Oncologists (ASCO) this summer was approved by the FDA today. This drug is the first in a new family of medicines called anti-CTLA 4 inhibitors.

Approval Date:

Fri, 03/25/2011

Company:

Bristol-Myers squibb

Tags: Oncology (Cancer), anti-CTLA 4, ASCO, BMS 734016, cancer, ECOG, FDA, immune system, induction phase, ipi, malignant melanoma, MDX 010, Melanoma, metastasis, skin cancer, Temodar, temozolomide, Yervoy

Yervoy (ipilimumab) melanoma immune-based therapy at FDA Feb 9, 2011

firework explosion Activatng the immune system is a relatively new model for attacking cancer, but it appears to be coming of age. While "true breakthrough" is a term rarely applied in most treatments, ipilimumab (proposed brand-Yervoy) may be just that for patients with melanoma.

Tags: Abnormal Cholesterol, Arthritis, Chronic Pain, Diabetes, Heart Attacks, High Blood Pressure, Oncology (Cancer), Osteoporosis, Poor Leg Circulation (PAD), Side Effects, Stroke, Weight Loss, advanced melanoma, BLA 125377, cancer response, chemotherapy, clinical trials.gov, combination chemo, CTLA, CTLA-4, cytotoxic T lymphocyte, immune chemotherapy, ipilimumab, Melanoma, skin cancer, T-Lymphocyte associated antigen, Yervoy

This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.